Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CBMNC in preterm infants
NCT03053076Phase 1Unknown
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous umbilical cord blood-derived mononuclear cells in preterm birth (2 arms), sponsored by Guangdong Women and Children Hospital. Primary endpoint: Number of patients who died at 21 days. Status: unknown.
02
Drugs
autologous umbilical cord blood-derived mononuclear cells
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT03053076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053076.